Category Archives: Global News Feed

Basel, April 6, 2022 — Novartis today announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval to Vijoice® (alpelisib) for the treatment of adult and pediatric patients 2 years of age and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS) who require systemic therapy.1 Vijoice is the first FDA-approved treatment for PROS, a spectrum of rare conditions characterized by overgrowths and blood vessel anomalies impacting an estimated 14 people per million.2,3 In accordance with the Accelerated Approval Program, continued approval may be contingent upon verification and description of clinical benefit from confirmatory evidence.

View original post here:
FDA approves Novartis Vijoice® (alpelisib) as first and only treatment for select patients with PIK3CA-Related Overgrowth Spectrum (PROS)

Basel, April 6, 2022 — Sandoz today announces the extension and expansion until January 31, 2025 of its strategic collaboration agreement with Ares Genetics (Ares), aimed at driving cutting-edge digital solutions in the global fight against antimicrobial resistance (AMR).

Read the original post:
Sandoz extends collaboration agreement to drive cutting-edge digital solutions in global fight against antimicrobial resistance (AMR)

Guerbet strengthens its Executive Committee with the appointment of Charlotte Bamière,   General Counsel

The rest is here:
Guerbet strengthens its Executive Committee with the appointment of Charlotte Bamière, General Counsel

LIfT BioSciences N-LIfT cell therapy shows complete and superior cell killing in solid tumour organoids compared to Keytruda

Visit link:
LIfT BioSciences N-LIfT cell therapy shows complete and superior cell killing in solid tumour organoids compared to Keytruda

Company announcement no. 03/2022

See the original post here:
Chr. Hansen Holding A/S Interim Report Q2 2021/22

TORONTO, March 24, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTCMKTS: CMNDF) (“Clearmind” or the "Company"), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, announced that its CEO, Dr. Adi Zuloff-Shani and Mark Haden, VP Business Development, will be presenting in the Psychedelic Capital: March 2022 virtual event.

Link:
Clearmind Medicine to Partner with Microdose for Psychedelic Capital: Mar 2022 Today, Thursday, March 24th

Saint-Herblain (France), March 24, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced today the filing of its 2021 Universal Registration Document (URD) with the French Financial Markets Authority (AMF) on March 23, 2022 under the filing number D.22-0140 and its Form 20-F with the U.S. Securities and Exchange Commission (SEC) on March 24, 2022.

See more here:
Valneva Announces Filing of 2021 Universal Registration Document and US Form 20-F

Topline data from Phase 2a trial of tegoprubart in ALS expected in 2Q 2022

Read more:
Eledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Operating and Financial Results

RESEARCH TRIANGLE PARK, N.C., March 24, 2022 (GLOBE NEWSWIRE) -- Opticyte® Amniotic Ocular Matrix, a product of Research Triangle Park-based Merakris Therapeutics, has gotten the attention of a leading trade publication directed at optometrists.

Read the original post:
Study in Modern Optometry Shows Effectiveness Of Merakris Therapeutics’ Eye Product, Opticyte® Matrix

Five ongoing clinical trials evaluating candidates ERAS-007 (ERKi), ERAS-601 (SHP2i), and ERAS-801 (CNS-penetrant EGFRi)

Continued here:
Erasca Reports Fourth Quarter 2021 Financial Results and Business Updates